Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241126 | 0.91 | CCR5 (0.55) | CCR5GPR119NR3C1MMP13MAPT | |
| SCHEMBL4241131 | 0.91 | CCR5 (0.55) | CCR5GPR119NR3C1MMP13MAPT | |
| SCHEMBL4240590 | 0.89 | CCR5 (0.48) | CCR5GPR119MMP13MAPTNPC1 | |
| SCHEMBL4236429 | 0.86 | GPR119 (0.47) | CCR5GPR119MAPTNPC1ALDH1A1 | |
| SCHEMBL4236631 | 0.82 | CCR5 (0.51) | CCR5GPR119MMP13MAPTNPC1 | |
| SCHEMBL4236630 | 0.82 | CCR5 (0.51) | CCR5GPR119MMP13MAPTNPC1 | |
| SCHEMBL4236013 | 0.80 | CCR5 (0.68) | CCR5 | |
| SCHEMBL4245272 | 0.80 | CCR5 (0.44) | CCR5GPR119MMP13MAPTNPC1 | |
| SCHEMBL4244414 | 0.79 | CCR5 (0.53) | CCR5GPR119MAPTNPC1ALDH1A1 | |
| SCHEMBL4243472 | 0.78 | GPR119 (0.47) | CCR5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | CCR5 1/4885GPR119 207/4885NR3C1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.